Cormorant Asset Management, LP
Insider CIK 1583977 · EYPT 10% owner · PTI 10% owner · APLS 10% owner · AVIR · CRBP 10% owner · TPTX 10% owner · RNA · AXNX 10% owner · OKUR 10% owner · KZR 10% owner · BIOA · RXDX · AKUS · RAIN · KNSA 10% owner · OLMA · ERAS Director, 10% owner · AARD · PYXS · ELEV · ICVX · IMRX 10% owner · AVTE · DSGN · MLTX 10% owner · GRNA · GLUE · BCAB · VIGL · DRUG 10% owner · AMAM 10% owner · BLSM 10% owner · BMEA Director, 10% owner · VERV · VTYX · TYRA · AMAM 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Hol | S Sale | 2026-10-29 | 2026-11-02 | 425,000 | $4.10 | $1.74M | 1,919,971 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion deriv | 2026-08-10 | 2026-08-10 | 1,599,993 | — | $0 | 0 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion deriv | 2026-08-10 | 2026-08-10 | 1,701,541 | — | $0 | 0 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion | 2026-08-10 | 2026-08-10 | 1,701,541 | — | $0 | 3,301,534 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion | 2026-08-10 | 2026-08-10 | 1,599,993 | — | $0 | 1,599,993 | SEC↗ |
| BLSM BlossomHill Therapeutics, | P Buy | 2026-08-10 | 2026-08-10 | 312,500 | $16.00 | $5.00M | 3,614,034 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion deriv | 2026-08-10 | 2026-08-10 | 1,701,541 | — | — | 0 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion deriv | 2026-08-10 | 2026-08-10 | 1,599,993 | — | — | 0 | SEC↗ |
| BLSM BlossomHill Therapeutics, | P Buy | 2026-08-10 | 2026-08-10 | 312,500 | $16.00 | $5.00M | 3,614,034 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion | 2026-08-10 | 2026-08-10 | 1,701,541 | — | — | 3,301,534 | SEC↗ |
| BLSM BlossomHill Therapeutics, | C Conversion | 2026-08-10 | 2026-08-10 | 1,599,993 | — | — | 1,599,993 | SEC↗ |
| BLSM BlossomHill Therapeutics, | A Award deriv | 2026-08-06 | 2026-08-10 | 23,904 | — | $0 | 23,904 | SEC↗ |
| BLSM BlossomHill Therapeutics, | A Award deriv | 2026-08-06 | 2026-08-10 | 23,904 | — | $0 | 23,904 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | S Sale | 2026-04-28 | 2026-04-30 | 109,331 | $89.50 | $9.79M | 950,000 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | S Sale | 2025-12-11 | 2025-12-15 | 30,029 | $11.46 | $344.1K | 2,344,971 | SEC↗ |
| EYPT EyePoint, Inc. | S Sale | 2025-12-04 | 2025-12-08 | 60,000 | $15.70 | $942.0K | 8,265,000 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | S Sale | 2025-09-30 | 2025-10-01 | 5,827 | $6.96 | $40.6K | 1,994,173 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | S Sale | 2025-09-29 | 2025-10-01 | 2,800,000 | $6.61 | $18.51M | 2,000,000 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | S Sale | 2025-09-29 | 2025-10-01 | 3,390,943 | $7.58 | $25.70M | 4,800,000 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | S Sale | 2025-09-29 | 2025-10-01 | 70,748 | $9.38 | $663.6K | 8,423,403 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | S Sale | 2025-09-29 | 2025-10-01 | 232,460 | $8.40 | $1.95M | 8,190,943 | SEC↗ |
| BMEA Biomea Fusion, Inc. | A Award deriv | 2025-06-11 | 2025-06-13 | 91,970 | — | $0 | 91,970 | SEC↗ |
| OKUR OnKure Therapeutics, Inc. | S Sale | 2025-05-15 | 2025-05-19 | 1,813,439 | $1.85 | $3.35M | 0 | SEC↗ |
| OKUR OnKure Therapeutics, Inc. | S Sale | 2025-05-12 | 2025-05-14 | 24,300 | $1.99 | $48.4K | 1,813,439 | SEC↗ |
| AARD Aardvark Therapeutics, Inc | C Conversion deriv | 2025-02-14 | 2025-02-19 | 6,780,810 | — | $0 | 0 | SEC↗ |
| AARD Aardvark Therapeutics, Inc | C Conversion | 2025-02-14 | 2025-02-19 | 800,189 | — | $0 | 800,189 | SEC↗ |
| AARD Aardvark Therapeutics, Inc | P Buy | 2025-02-14 | 2025-02-19 | 187,500 | $16.00 | $3.00M | 987,689 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | P Buy | 2024-11-04 | 2024-11-06 | 184,331 | $21.70 | $4.00M | 1,059,331 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | P Buy | 2024-10-16 | 2024-10-17 | 39,743 | $23.22 | $922.8K | 864,743 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | P Buy | 2024-10-16 | 2024-10-17 | 3,107 | $25.22 | $78.4K | 875,000 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | P Buy | 2024-10-16 | 2024-10-17 | 7,150 | $24.03 | $171.8K | 871,893 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | P Buy | 2024-10-15 | 2024-10-17 | 4,609 | $12.35 | $56.9K | 825,000 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | P Buy | 2024-10-15 | 2024-10-17 | 19,169 | $11.72 | $224.7K | 820,391 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | P Buy | 2024-10-15 | 2024-10-17 | 2,700 | $9.26 | $25.0K | 801,222 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | P Buy | 2024-10-15 | 2024-10-17 | 8,900 | $7.31 | $65.1K | 795,922 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | P Buy | 2024-10-15 | 2024-10-17 | 33,343 | $6.42 | $214.1K | 787,022 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | P Buy | 2024-10-15 | 2024-10-17 | 63,173 | $5.92 | $374.0K | 753,679 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | P Buy | 2024-10-15 | 2024-10-17 | 238,097 | $4.53 | $1.08M | 690,506 | SEC↗ |
| DRUG BRIGHT MINDS BIOSCIENCES I | P Buy | 2024-10-15 | 2024-10-17 | 2,600 | $8.80 | $22.9K | 798,522 | SEC↗ |
| BIOA BioAge Labs, Inc. | C Conversion deriv | 2024-09-27 | 2024-10-01 | 5,263,772 | — | $0 | 0 | SEC↗ |
| BIOA BioAge Labs, Inc. | C Conversion | 2024-09-27 | 2024-10-01 | 1,179,529 | — | $0 | 1,179,529 | SEC↗ |
| BIOA BioAge Labs, Inc. | P Buy | 2024-09-27 | 2024-10-01 | 450,000 | $18.00 | $8.10M | 1,629,529 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-09-20 | 2024-09-24 | 47,564 | $21.47 | $1.02M | 2,349,231 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-09-20 | 2024-09-24 | 66,088 | $19.61 | $1.30M | 2,162,116 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-09-20 | 2024-09-24 | 139,551 | $20.42 | $2.85M | 2,301,667 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-09-20 | 2024-09-24 | 25,769 | $22.23 | $572.8K | 2,375,000 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-09-20 | 2024-09-24 | 45,085 | $17.48 | $788.1K | 2,070,085 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-09-20 | 2024-09-24 | 25,943 | $18.36 | $476.3K | 2,096,028 | SEC↗ |
| BMEA Biomea Fusion, Inc. | A Award deriv | 2024-06-12 | 2024-06-13 | 51,025 | — | $0 | 51 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2024-05-06 | 2024-05-08 | 642,847 | $11.70 | $7.52M | 8,117,847 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2024-05-06 | 2024-05-08 | 207,153 | $12.36 | $2.56M | 8,325,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2024-04-18 | 2024-04-22 | 395,244 | $17.62 | $6.96M | 7,288,479 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2024-04-18 | 2024-04-22 | 186,521 | $18.90 | $3.53M | 7,475,000 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-04-01 | 2024-04-03 | 100 | $3.05 | $305 | 3,294,773 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-04-01 | 2024-04-03 | 600 | $3.03 | $1.8K | 3,294,173 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-04-01 | 2024-04-03 | 100 | $3.07 | $307 | 3,295,173 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-04-01 | 2024-04-03 | 300 | $3.07 | $921 | 3,294,873 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-04-01 | 2024-04-03 | 398,600 | $2.90 | $1.16M | 2,895,273 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-04-01 | 2024-04-03 | 10 | $3.01 | $30 | 3,294,163 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-04-01 | 2024-04-03 | 10 | $2.98 | $30 | 3,294,153 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-04-01 | 2024-04-03 | 280 | $2.97 | $832 | 3,293,873 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-03-15 | 2024-03-18 | 400,000 | $2.14 | $856.0K | 3,295,273 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-03-14 | 2024-03-18 | 345,266 | $3.24 | $1.12M | 3,859,098 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-03-14 | 2024-03-18 | 98,570 | $4.25 | $418.9K | 3,760,528 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-03-14 | 2024-03-18 | 54,215 | $5.37 | $291.1K | 3,706,313 | SEC↗ |
| IMRX Immuneering Corp | S Sale | 2024-03-14 | 2024-03-18 | 11,040 | $5.97 | $65.9K | 3,695,273 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-03-08 | 2024-03-11 | 29,342 | $41.23 | $1.21M | 1,754,342 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-03-08 | 2024-03-11 | 156,597 | $45.26 | $7.09M | 2,016,138 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-03-08 | 2024-03-11 | 8,862 | $45.96 | $407.3K | 2,025,000 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-03-08 | 2024-03-11 | 18,548 | $43.26 | $802.4K | 1,797,873 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-03-08 | 2024-03-11 | 61,668 | $44.62 | $2.75M | 1,859,541 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-03-08 | 2024-03-11 | 24,983 | $42.25 | $1.06M | 1,779,325 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-03-07 | 2024-03-11 | 102,140 | $41.23 | $4.21M | 1,725,000 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-03-07 | 2024-03-11 | 46,799 | $37.82 | $1.77M | 1,521,799 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-03-07 | 2024-03-11 | 10,736 | $39.13 | $420.1K | 1,532,535 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-03-07 | 2024-03-11 | 90,325 | $39.99 | $3.61M | 1,622,860 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-02-02 | 2024-02-06 | 750,000 | $19.00 | $14.25M | 1,475,000 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 16,484 | $36.53 | $602.2K | 678,046 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 32,295 | $35.83 | $1.16M | 661,562 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 31,549 | $34.62 | $1.09M | 629,267 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 18,055 | $33.71 | $608.6K | 597,718 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 3,866 | $32.47 | $125.5K | 579,663 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 4,125 | $31.86 | $131.4K | 575,797 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 2,654 | $31.00 | $82.3K | 571,672 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 43,754 | $37.49 | $1.64M | 721,800 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 3,200 | $38.49 | $123.2K | 725,000 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 29,244 | $29.42 | $860.4K | 569,018 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 14,388 | $25.73 | $370.2K | 456,756 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 15,243 | $26.66 | $406.4K | 471,999 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 36,747 | $27.70 | $1.02M | 508,746 | SEC↗ |
| CRBP Corbus Pharmaceuticals Hol | P Buy | 2024-01-26 | 2024-01-30 | 31,028 | $28.82 | $894.2K | 539,774 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2024-01-11 | 2024-01-11 | 750,000 | $19.75 | $14.81M | 6,893,235 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2024-01-09 | 2024-01-11 | 105,000 | $21.32 | $2.24M | 6,143,235 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-08 | 2023-12-12 | 588,235 | $17.00 | $10.00M | 6,038,235 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 19,866 | $33.75 | $670.5K | 5,441,740 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 41,824 | $33.08 | $1.38M | 5,421,874 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 8,260 | $34.49 | $284.9K | 5,450,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 321,259 | $18.80 | $6.04M | 3,852,202 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 86,713 | $31.83 | $2.76M | 5,380,050 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 15,582 | $30.74 | $479.0K | 5,293,337 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 18,601 | $29.91 | $556.4K | 5,277,755 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 8,168 | $28.78 | $235.1K | 5,259,154 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 27,425 | $27.87 | $764.3K | 5,250,986 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 53,109 | $26.73 | $1.42M | 5,223,561 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 65,086 | $25.88 | $1.68M | 5,170,452 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 39,899 | $24.87 | $992.3K | 5,105,366 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 37,081 | $24.01 | $890.3K | 5,065,467 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 28,090 | $22.80 | $640.5K | 5,028,386 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 79,805 | $21.87 | $1.75M | 5,000,296 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 122,625 | $20.62 | $2.53M | 4,920,491 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | P Buy | 2023-12-04 | 2023-12-06 | 945,664 | $19.88 | $18.80M | 4,797,866 | SEC↗ |
| AMAM Ambrx Biopharma, Inc. | P Buy | 2023-10-23 | 2023-10-25 | 1,307,311 | $6.99 | $9.14M | 11,231,000 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | P Buy | 2023-10-05 | 2023-10-10 | 58,839 | $59.90 | $3.52M | 8,494,151 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | P Buy | 2023-10-04 | 2023-10-04 | 67,814 | $57.32 | $3.89M | 8,435,312 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | P Buy | 2023-10-03 | 2023-10-04 | 150,487 | $57.25 | $8.62M | 8,367,498 | SEC↗ |
| MLTX MoonLake Immunotherapeutic | P Buy | 2023-10-02 | 2023-10-04 | 74,911 | $57.37 | $4.30M | 8,217,011 | SEC↗ |
| AMAM Ambrx Biopharma Inc. | P Buy | 2023-09-18 | 2023-09-19 | 751,233 | $9.24 | $6.94M | 69,465,823 | SEC↗ |
| AMAM Ambrx Biopharma Inc. | P Buy | 2023-09-15 | 2023-09-19 | 1,401,505 | $9.05 | $12.68M | 68,714,590 | SEC↗ |
| GRNA GreenLight Biosciences Hol | S Sale | 2023-07-20 | 2023-07-24 | 9,188,659 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | A Award deriv | 2023-06-22 | 2023-06-26 | 60,000 | — | $0 | 60,000 | SEC↗ |
| BMEA Biomea Fusion, Inc. | A Award deriv | 2023-06-14 | 2023-06-16 | 6,989 | — | $0 | 6,989 | SEC↗ |
| AMAM Ambrx Biopharma Inc. | P Buy | 2023-04-20 | 2023-04-20 | 886,634 | $11.60 | $10.28M | 67,313,085 | SEC↗ |
| AMAM Ambrx Biopharma Inc. | P Buy | 2023-04-19 | 2023-04-20 | 951,909 | $11.15 | $10.61M | 66,426,451 | SEC↗ |
| AMAM Ambrx Biopharma Inc. | P Buy | 2023-04-18 | 2023-04-20 | 3,376,646 | $11.27 | $38.05M | 65,474,542 | SEC↗ |
| AMAM Ambrx Biopharma Inc. | P Buy | 2023-04-17 | 2023-04-17 | 562,121 | $10.67 | $6.00M | 62,097,896 | SEC↗ |
| AMAM Ambrx Biopharma Inc. | P Buy | 2023-04-14 | 2023-04-17 | 841,967 | $9.96 | $8.39M | 61,535,775 | SEC↗ |
| AMAM Ambrx Biopharma Inc. | P Buy | 2023-04-13 | 2023-04-17 | 1,193,808 | $9.16 | $10.94M | 60,693,808 | SEC↗ |
| BMEA Biomea Fusion, Inc. | P Buy | 2023-03-30 | 2023-04-03 | 400,000 | $30.00 | $12.00M | 3,570,872 | SEC↗ |
| AMAM Ambrx Biopharma Inc. | P Buy | 2023-03-16 | 2023-03-16 | 500,000 | $10.15 | $5.08M | 53,500,000 | SEC↗ |
| AMAM Ambrx Biopharma Inc. | P Buy | 2023-03-15 | 2023-03-16 | 250,000 | $10.60 | $2.65M | 53,000,000 | SEC↗ |
| AMAM Ambrx Biopharma Inc. | P Buy | 2023-03-14 | 2023-03-16 | 250,000 | $9.95 | $2.49M | 52,750,000 | SEC↗ |
| ERAS Erasca, Inc. | P Buy | 2022-12-13 | 2022-12-20 | 307,692 | $6.50 | $2.00M | 10,813,246 | SEC↗ |
| ERAS Erasca, Inc. | P Buy | 2022-12-13 | 2022-12-21 | 307,692 | $6.50 | $2.00M | 10,813,246 | SEC↗ |
| BMEA Biomea Fusion, Inc. | A Award deriv | 2022-06-22 | 2022-06-24 | 23,867 | — | $0 | 23,867 | SEC↗ |
| VIGL Vigil Neuroscience, Inc. | C Conversion deriv | 2022-01-11 | 2022-01-13 | 616,786 | — | $0 | 0 | SEC↗ |
| VIGL Vigil Neuroscience, Inc. | C Conversion | 2022-01-11 | 2022-01-13 | 616,786 | — | $0 | 616,786 | SEC↗ |
| VTYX Ventyx Biosciences, Inc. | C Conversion deriv | 2021-10-25 | 2021-10-27 | 548,288 | — | $0 | 0 | SEC↗ |
| VTYX Ventyx Biosciences, Inc. | C Conversion deriv | 2021-10-25 | 2021-10-27 | 237,015 | — | $0 | 0 | SEC↗ |
| VTYX Ventyx Biosciences, Inc. | C Conversion | 2021-10-25 | 2021-10-27 | 785,303 | — | $0 | 785,303 | SEC↗ |
| VTYX Ventyx Biosciences, Inc. | P Buy | 2021-10-25 | 2021-10-27 | 625,000 | $16.00 | $10.00M | 1,410,303 | SEC↗ |
| PYXS Pyxis Oncology, Inc. | C Conversion deriv | 2021-10-13 | 2021-10-15 | 668,854 | — | $0 | 0 | SEC↗ |
| PYXS Pyxis Oncology, Inc. | C Conversion | 2021-10-13 | 2021-10-15 | 668,854 | — | $0 | 668,854 | SEC↗ |
| PYXS Pyxis Oncology, Inc. | P Buy | 2021-10-13 | 2021-10-15 | 450,000 | $16.00 | $7.20M | 1,118,854 | SEC↗ |
| TYRA Tyra Biosciences, Inc. | C Conversion deriv | 2021-09-17 | 2021-09-21 | 757,432 | — | $0 | 0 | SEC↗ |
| TYRA Tyra Biosciences, Inc. | C Conversion | 2021-09-17 | 2021-09-21 | 757,432 | — | $0 | 757,432 | SEC↗ |
| TYRA Tyra Biosciences, Inc. | P Buy | 2021-09-17 | 2021-09-21 | 312,500 | $16.00 | $5.00M | 1,069,932 | SEC↗ |
| IMRX Immuneering Corp | C Conversion deriv | 2021-08-03 | 2021-08-05 | 1,702,628 | — | $0 | 0 | SEC↗ |
| IMRX Immuneering Corp | P Buy | 2021-08-03 | 2021-08-05 | 550,000 | $15.00 | $8.25M | 2,252,628 | SEC↗ |
| IMRX Immuneering Corp | C Conversion | 2021-08-03 | 2021-08-05 | 1,702,628 | — | $0 | 1,702,628 | SEC↗ |
| ICVX Icosavax, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 426,393 | — | $0 | 0 | SEC↗ |
| ICVX Icosavax, Inc. | C Conversion | 2021-08-02 | 2021-08-04 | 426,393 | — | $0 | 426,393 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion deriv | 2021-07-20 | 2021-07-22 | 4,000,000 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion deriv | 2021-07-20 | 2021-07-22 | 1,388,887 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion deriv | 2021-07-20 | 2021-07-22 | 4,166,666 | — | $0 | 0 | SEC↗ |
| ERAS Erasca, Inc. | P Buy | 2021-07-20 | 2021-07-22 | 950,000 | $16.00 | $15.20M | 10,505,553 | SEC↗ |
| ERAS Erasca, Inc. | C Conversion | 2021-07-20 | 2021-07-22 | 9,555,553 | — | $0 | 9,555,553 | SEC↗ |
| AVTE Aerovate Therapeutics, Inc | C Conversion deriv | 2021-07-02 | 2021-07-07 | 1,530,691 | — | $0 | 0 | SEC↗ |
| AVTE Aerovate Therapeutics, Inc | P Buy | 2021-07-02 | 2021-07-07 | 500,000 | $14.00 | $7.00M | 2,030,691 | SEC↗ |
| AVTE Aerovate Therapeutics, Inc | C Conversion | 2021-07-02 | 2021-07-07 | 1,530,691 | — | $0 | 1,530,691 | SEC↗ |
| ELEV Elevation Oncology, Inc. | C Conversion deriv | 2021-06-29 | 2021-07-01 | 1,983,168 | — | $0 | 0 | SEC↗ |
| ELEV Elevation Oncology, Inc. | P Buy | 2021-06-29 | 2021-07-01 | 250,000 | $16.00 | $4.00M | 2,233,168 | SEC↗ |
| ELEV Elevation Oncology, Inc. | C Conversion | 2021-06-29 | 2021-07-01 | 1,983,168 | — | $0 | 1,983,168 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | C Conversion deriv | 2021-06-28 | 2021-06-30 | 2,124,343 | — | $0 | 0 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | C Conversion deriv | 2021-06-28 | 2021-06-30 | 477,857 | — | $0 | 0 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | P Buy | 2021-06-28 | 2021-06-30 | 600,000 | $19.00 | $11.40M | 3,202,200 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | C Conversion | 2021-06-28 | 2021-06-30 | 2,602,200 | — | $0 | 2,602,200 | SEC↗ |
| VERV Verve Therapeutics, Inc. | C Conversion deriv | 2021-06-21 | 2021-06-23 | 709,224 | — | $0 | 0 | SEC↗ |
| VERV Verve Therapeutics, Inc. | C Conversion | 2021-06-21 | 2021-06-23 | 709,224 | — | $0 | 709,224 | SEC↗ |
| VERV Verve Therapeutics, Inc. | P Buy | 2021-06-21 | 2021-06-23 | 275,000 | $19.00 | $5.22M | 984,224 | SEC↗ |
| RAIN Rain Therapeutics Inc. | C Conversion deriv | 2021-04-27 | 2021-04-29 | 2,512,561 | — | $0 | 0 | SEC↗ |
| RAIN Rain Therapeutics Inc. | P Buy | 2021-04-27 | 2021-04-29 | 450,000 | $17.00 | $7.65M | 2,776,657 | SEC↗ |
| RAIN Rain Therapeutics Inc. | C Conversion | 2021-04-27 | 2021-04-29 | 2,326,657 | — | $0 | 2,326,657 | SEC↗ |
| BMEA Biomea Fusion, Inc. | C Conversion deriv | 2021-04-20 | 2021-04-22 | 2,270,872 | — | $0 | 0 | SEC↗ |
| BMEA Biomea Fusion, Inc. | P Buy | 2021-04-20 | 2021-04-22 | 900,000 | $17.00 | $15.30M | 3,170,872 | SEC↗ |
| BMEA Biomea Fusion, Inc. | C Conversion | 2021-04-20 | 2021-04-22 | 2,270,872 | — | $0 | 2,270,872 | SEC↗ |
| BMEA Biomea Fusion, Inc. | A Award deriv | 2021-04-15 | 2021-04-19 | 28,911 | — | $0 | 28,911 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion deriv | 2021-03-30 | 2021-04-01 | 1,404,953 | — | $0 | 0 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion deriv | 2021-03-30 | 2021-04-01 | 2,959,891 | — | $0 | 0 | SEC↗ |
| DSGN Design Therapeutics, Inc. | C Conversion | 2021-03-30 | 2021-04-01 | 4,364,844 | — | $0 | 4,364,844 | SEC↗ |
| DSGN Design Therapeutics, Inc. | P Buy | 2021-03-30 | 2021-04-01 | 750,000 | $20.00 | $15.00M | 5,114,844 | SEC↗ |
| RXDX Prometheus Biosciences, In | C Conversion deriv | 2021-03-16 | 2021-03-18 | 763,327 | — | $0 | 0 | SEC↗ |
| RXDX Prometheus Biosciences, In | C Conversion deriv | 2021-03-16 | 2021-03-18 | 1,084,696 | — | $0 | 0 | SEC↗ |
| RXDX Prometheus Biosciences, In | C Conversion | 2021-03-16 | 2021-03-18 | 1,848,022 | — | $0 | 1,848,022 | SEC↗ |
| RXDX Prometheus Biosciences, In | P Buy | 2021-03-16 | 2021-03-18 | 375,000 | $19.00 | $7.13M | 2,223,022 | SEC↗ |
| BCAB BioAtla, Inc. | C Conversion deriv | 2020-12-18 | 2020-12-22 | 1,492,060 | — | $0 | 0 | SEC↗ |
| BCAB BioAtla, Inc. | C Conversion | 2020-12-18 | 2020-12-22 | 1,492,060 | — | $0 | 1,492,060 | SEC↗ |
| BCAB BioAtla, Inc. | P Buy | 2020-12-18 | 2020-12-22 | 800,000 | $18.00 | $14.40M | 2,292,060 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | C Conversion deriv | 2020-11-23 | 2020-11-23 | 723,177 | — | $0 | 0 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | C Conversion deriv | 2020-11-23 | 2020-11-23 | 2,122,367 | — | $0 | 0 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | C Conversion | 2020-11-23 | 2020-11-23 | 2,845,544 | — | $0 | 2,845,544 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | P Buy | 2020-11-23 | 2020-11-23 | 425,000 | $19.00 | $8.07M | 3,270,544 | SEC↗ |
| AVIR Atea Pharmaceuticals, Inc. | C Conversion deriv | 2020-11-03 | 2020-11-05 | 2,631,580 | — | $0 | 0 | SEC↗ |
| AVIR Atea Pharmaceuticals, Inc. | C Conversion deriv | 2020-11-03 | 2020-11-05 | 712,250 | — | $0 | 0 | SEC↗ |
| AVIR Atea Pharmaceuticals, Inc. | C Conversion deriv | 2020-11-03 | 2020-11-05 | 1,650,165 | — | $0 | 0 | SEC↗ |
| AVIR Atea Pharmaceuticals, Inc. | C Conversion deriv | 2020-11-03 | 2020-11-05 | 1,000,000 | — | $0 | 0 | SEC↗ |
| AVIR Atea Pharmaceuticals, Inc. | C Conversion deriv | 2020-11-03 | 2020-11-05 | 417,360 | — | $0 | 0 | SEC↗ |
| AVIR Atea Pharmaceuticals, Inc. | C Conversion | 2020-11-03 | 2020-11-05 | 6,411,355 | — | $0 | 6,411,355 | SEC↗ |
| AKUS Akouos, Inc. | C Conversion deriv | 2020-06-30 | 2020-07-02 | 499,989 | — | $0 | 0 | SEC↗ |
| AKUS Akouos, Inc. | P Buy | 2020-06-30 | 2020-07-02 | 290,000 | $17.00 | $4.93M | 789,989 | SEC↗ |
| AKUS Akouos, Inc. | C Conversion | 2020-06-30 | 2020-07-02 | 499,989 | — | $0 | 499,989 | SEC↗ |
| RNA Avidity Biosciences, Inc. | C Conversion deriv | 2020-06-16 | 2020-06-18 | 2,214,545 | — | $0 | 0 | SEC↗ |
| RNA Avidity Biosciences, Inc. | C Conversion | 2020-06-16 | 2020-06-18 | 2,214,545 | — | $0 | 2,214,545 | SEC↗ |
| RNA Avidity Biosciences, Inc. | P Buy | 2020-06-16 | 2020-06-18 | 300,000 | $18.00 | $5.40M | 2,514,545 | SEC↗ |
| TPTX Turning Point Therapeutics | M Exercise | 2019-05-14 | 2019-05-16 | 23,268 | $2.19 | $51.0K | 3,122,367 | SEC↗ |
| TPTX Turning Point Therapeutics | M Exercise deriv | 2019-05-13 | 2019-05-16 | 23,268 | — | $0 | 0 | SEC↗ |
| TPTX Turning Point Therapeutics | P Buy | 2019-04-22 | 2019-04-25 | 400,000 | $18.00 | $7.20M | 3,099,099 | SEC↗ |
| AXNX Axonics Modulation Technol | C Conversion deriv | 2018-10-31 | 2018-11-02 | 599,999 | — | $0 | 0 | SEC↗ |
| AXNX Axonics Modulation Technol | C Conversion deriv | 2018-10-31 | 2018-11-02 | 552,495 | — | $0 | 0 | SEC↗ |
| AXNX Axonics Modulation Technol | C Conversion | 2018-10-31 | 2018-11-02 | 552,495 | — | $0 | 1,152,494 | SEC↗ |
| AXNX Axonics Modulation Technol | P Buy | 2018-10-31 | 2018-11-02 | 133,333 | $15.00 | $2.00M | 1,285,827 | SEC↗ |
| AXNX Axonics Modulation Technol | C Conversion | 2018-10-31 | 2018-11-02 | 599,999 | — | $0 | 599,999 | SEC↗ |
| KZR Kezar Life Sciences, Inc. | C Conversion deriv | 2018-06-25 | 2018-06-27 | 315,488 | — | $0 | 0 | SEC↗ |
| KZR Kezar Life Sciences, Inc. | C Conversion deriv | 2018-06-25 | 2018-06-27 | 1,007,421 | — | $0 | 0 | SEC↗ |
| KZR Kezar Life Sciences, Inc. | C Conversion | 2018-06-25 | 2018-06-27 | 315,488 | — | $0 | 315,488 | SEC↗ |
| KZR Kezar Life Sciences, Inc. | P Buy | 2018-06-25 | 2018-06-27 | 250,000 | $15.00 | $3.75M | 1,572,909 | SEC↗ |
| KZR Kezar Life Sciences, Inc. | C Conversion | 2018-06-25 | 2018-06-27 | 1,007,421 | — | $0 | 1,322,909 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | C Conversion deriv | 2018-05-29 | 2018-05-31 | 830,999 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | C Conversion | 2018-05-29 | 2018-05-31 | 830,999 | — | $0 | 830,999 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | P Buy | 2018-05-29 | 2018-05-31 | 69,444 | $18.00 | $1.25M | 900,443 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | S Sale | 2017-12-14 | 2017-12-18 | 504,027 | $4.88 | $2.46M | 3,300,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | C Conversion deriv | 2017-11-13 | 2017-11-14 | 2,098,581 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | C Conversion deriv | 2017-11-13 | 2017-11-14 | 303,916 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | P Buy | 2017-11-13 | 2017-11-14 | 1,071,428 | $14.00 | $15.00M | 3,473,925 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | C Conversion | 2017-11-13 | 2017-11-14 | 2,402,497 | — | $0 | 2,402,497 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-12-13 | 2016-12-14 | 21,301 | $10.98 | $233.9K | 3,804,027 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-12-12 | 2016-12-14 | 100,000 | $10.79 | $1.08M | 3,782,726 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-12-08 | 2016-12-09 | 21,819 | $10.93 | $238.5K | 3,682,726 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-12-07 | 2016-12-09 | 22,598 | $10.74 | $242.7K | 3,660,907 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-12-06 | 2016-12-06 | 8,216 | $10.89 | $89.5K | 3,638,309 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-12-05 | 2016-12-06 | 29,757 | $10.78 | $320.8K | 3,630,093 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-12-02 | 2016-12-06 | 50,000 | $10.48 | $524.0K | 3,600,336 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-12-01 | 2016-12-01 | 41,984 | $10.11 | $424.5K | 3,550,336 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-29 | 2016-12-01 | 128,407 | $10.28 | $1.32M | 3,508,352 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-23 | 2016-11-23 | 180,300 | $11.37 | $2.05M | 3,379,745 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-23 | 2016-11-23 | 200 | $10.67 | $2.1K | 3,379,945 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-22 | 2016-11-23 | 69,500 | $11.08 | $770.1K | 3,199,445 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-21 | 2016-11-23 | 111,863 | $11.64 | $1.30M | 3,129,945 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-14 | 2016-11-14 | 9,500 | $11.48 | $109.1K | 3,018,082 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-11 | 2016-11-14 | 21,200 | $11.46 | $243.0K | 3,008,582 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-10 | 2016-11-14 | 216,700 | $11.07 | $2.40M | 2,987,382 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-09 | 2016-11-14 | 12,100 | $9.68 | $117.1K | 2,770,682 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-07 | 2016-11-07 | 231,700 | $8.69 | $2.01M | 2,758,582 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-04 | 2016-11-07 | 2,597 | $7.27 | $18.9K | 2,453,497 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-04 | 2016-11-07 | 73,403 | $8.09 | $593.8K | 2,526,882 | SEC↗ |
| PTI PROTEOSTASIS THERAPEUTICS, | P Buy | 2016-11-03 | 2016-11-07 | 20,277 | $7.24 | $146.8K | 2,450,882 | SEC↗ |